NewsBenzingaプロパンク・バイオファーマ、PRPが膵臓がんの化学療法抵抗性を治療する可能性を裏付ける新たな前臨床データを発表;PRP単剤療法はがん細胞増殖を約50~54%抑制し、長期クローン形成生存を最大59%抑制した プロパンク・バイオファーマ、PRPが膵臓がんの化学療法抵抗性を治療する可能性を裏付ける新たな前臨床データを発表;PRP単剤療法はがん細胞増殖を約50~54%抑制し、長期クローン形成生存を最大59%抑制した Benzinga 2026.10.26 12:32 (GMT+0) Open on Benzinga Other news NRX Pharmaceuticals Q3 EPS $(0.05) Beats $(0.21) Estimate, Sales $1.159M Miss $1.300M Estimate HUYA Q3 Adj. EPS $0.03 Up From $0.02 YoY, Sales $261.441M Up From $237.147M YoY Adam Schiff Slams Corporate Executives Over Unreturned Trump Tariff Money: ‘Companies Got Tariff Refunds, Consumers Got…’ Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL Ford Recalls 60,956 Transit Vehicles Over Body Control Module Software Error That Can Shut Off Trailer Lights, Raising Crash Risk Top Wall Street Forecasters Revamp Energizer Expectations Ahead Of Q4 Earnings
Adam Schiff Slams Corporate Executives Over Unreturned Trump Tariff Money: ‘Companies Got Tariff Refunds, Consumers Got…’
Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL
Ford Recalls 60,956 Transit Vehicles Over Body Control Module Software Error That Can Shut Off Trailer Lights, Raising Crash Risk